---
title: "Clarity Pharmaceuticals (ASX:CU6): Executive Chair on Phase 3, Prostate Cancer & Radiopharma Growth"
description: "Can Clarity Pharmaceuticals (ASX:CU6) become a global leader in next-generation radiopharmaceuticals for prostate cancer? In this exclusive Homodeus Research webinar, Dr Alan Taylor, Executive Chair of Clarity Pharmaceuticals, discusses the company's copper-based radiopharmaceutical platform, progress across its Phase 3 clinical programs, and the landmark Co-PSMA study. The conversation covers CLARIFY, AMPLIFY and ACCURACY, the advantages of copper isotopes in cancer imaging, Clarity's intellectual property and manufacturing strategy, commercialisation plans, competitive positioning and the opportunity to expand the SAR platform beyond prostate cancer. Whether you're interested in biotechnology, nuclear medicine, oncology or ASX healthcare stocks, this interview provides an in-depth look at Clarity's clinical strategy and the key catalysts investors should be watching. TIMESTAMPS 00:00 Introduction 00:33 Three Reasons Investors Are Watching Clarity 01:14 Company Overview & Radiopharmaceutical Platform 02:53 Intellectual Property & Technology Foundation 04:55 Phase 3 Clinical Program Update 16:17 Co-PSMA Trial Results Explained 19:26 Investor Q&A Begins 24:48 Why CLARIFY Recruitment Took Longer Than Co-PSMA 29:26 Competition & Next-Generation PSMA Agents 31:48 Platform Expansion Beyond Prostate Cancer 33:50 Commercialisation Strategy 37:51 M&A, Partnerships & Industry Interest 39:28 Key Catalysts & Clinical Milestones 43:50 Closing Remarks FURTHER READING & LISTENING 🎧 GU Cast | Urology Podcast – \"Is Copper the new Gold??! Co-PSMA trial in European Urology\" https://www.podchaser.com/podcasts/gu-cast-urology-podcast-2221144/episodes/is-copper-the-new-gold-co-psma-292293994 📄 European Urology – Co-PSMA Trial Publication https://doi.org/10.1016/j.eururo.2026.03.001 These resources were referenced during the webinar and provide additional context around the Co-PSMA study and Cu-64 SAR-bisPSMA. ABOUT HOMODEUS RESEARCH Homodeus Research provides independent investor education through in-depth interviews with ASX-listed companies, helping investors better understand business models, industries and long-term investment opportunities. Enjoyed this interview? Subscribe to Homodeus Research for interviews with ASX-listed executives, industry experts and thought leaders across healthcare, technology, mining and emerging growth companies. DISCLAIMER This webinar is provided for educational purposes only and should not be considered financial advice. Always conduct your own research and seek advice from a licensed financial adviser before making investment decisions."
canonical_url: "https://homodeus.one/research/videos/9AUDFjA7_zA"
markdown_url: "https://homodeus.one/research/videos/9AUDFjA7_zA.md"
published_date: "2026-09-10T05:21:19+00:00"
modified_date: "2026-10-10T13:31:59.157Z"
thumbnail_url: "https://i2.ytimg.com/vi/9AUDFjA7_zA/hqdefault.jpg"
embed_url: "https://www.youtube.com/embed/9AUDFjA7_zA"
source_url: "https://www.youtube.com/watch?v=9AUDFjA7_zA"
access: "full"
source: "Homodeus Research"
---

# Clarity Pharmaceuticals (ASX:CU6): Executive Chair on Phase 3, Prostate Cancer & Radiopharma Growth

Published 2026-09-10T05:21:19+00:00.

Can Clarity Pharmaceuticals (ASX:CU6) become a global leader in next-generation radiopharmaceuticals for prostate cancer?

In this exclusive Homodeus Research webinar, Dr Alan Taylor, Executive Chair of Clarity Pharmaceuticals, discusses the company's copper-based radiopharmaceutical platform, progress across its Phase 3 clinical programs, and the landmark Co-PSMA study.

The conversation covers CLARIFY, AMPLIFY and ACCURACY, the advantages of copper isotopes in cancer imaging, Clarity's intellectual property and manufacturing strategy, commercialisation plans, competitive positioning and the opportunity to expand the SAR platform beyond prostate cancer.

Whether you're interested in biotechnology, nuclear medicine, oncology or ASX healthcare stocks, this interview provides an in-depth look at Clarity's clinical strategy and the key catalysts investors should be watching.

TIMESTAMPS

00:00 Introduction
00:33 Three Reasons Investors Are Watching Clarity
01:14 Company Overview & Radiopharmaceutical Platform
02:53 Intellectual Property & Technology Foundation
04:55 Phase 3 Clinical Program Update
16:17 Co-PSMA Trial Results Explained
19:26 Investor Q&A Begins
24:48 Why CLARIFY Recruitment Took Longer Than Co-PSMA
29:26 Competition & Next-Generation PSMA Agents
31:48 Platform Expansion Beyond Prostate Cancer
33:50 Commercialisation Strategy
37:51 M&A, Partnerships & Industry Interest
39:28 Key Catalysts & Clinical Milestones
43:50 Closing Remarks

FURTHER READING & LISTENING

🎧 GU Cast | Urology Podcast – "Is Copper the new Gold??! Co-PSMA trial in European Urology"
https://www.podchaser.com/podcasts/gu-cast-urology-podcast-2221144/episodes/is-copper-the-new-gold-co-psma-292293994

📄 European Urology – Co-PSMA Trial Publication
https://doi.org/10.1016/j.eururo.2026.03.001

These resources were referenced during the webinar and provide additional context around the Co-PSMA study and Cu-64 SAR-bisPSMA.

ABOUT HOMODEUS RESEARCH

Homodeus Research provides independent investor education through in-depth interviews with ASX-listed companies, helping investors better understand business models, industries and long-term investment opportunities.

Enjoyed this interview?

Subscribe to Homodeus Research for interviews with ASX-listed executives, industry experts and thought leaders across healthcare, technology, mining and emerging growth companies.

DISCLAIMER

This webinar is provided for educational purposes only and should not be considered financial advice. Always conduct your own research and seek advice from a licensed financial adviser before making investment decisions.

Watch: https://www.youtube.com/watch?v=9AUDFjA7_zA